Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2014

View Archived Issues

Novel FabI inhibitors with promising activity against staphylococcal infections

Cleave Biosciences initiates phase I trial of CB-5083 in patients with solid tumors

Arisaph Pharmaceuticals initiates phase II study of ARI-3037-MO in hypertriglyceridemia

Uncovering de novo mutations that underscore epileptic encephalopathies

FDA grants Vivolux clearance to conduct phase I/II trial of VLX-1570

Updated phase I results for MSC-2156119J in advanced solid tumors

Deciphera Pharmaceuticals patents novel agents for cancer and other disorders

Novel pyrrolotriazines disclosed by Bristol-Myers Squibb for arrhythmia

Aurigene Discovery Technologies designs new NAmPRTase inhibitors

Takeda Pharmaceutical divulges novel ROR-gamma antagonists

Scientists at Roche synthesize novel autotaxin inhibitors

FDA approves Uceris rectal foam for induction of remission of distal ulcerative colitis

MedImmune in-licenses Shionogi's ACS biologic research program

PET imaging of Abeta plaques using a novel 89Zr-labeled MAb

Striverdi Respimat inhalation spray now available in the U.S.

E-6005 shows efficacy and safety in early clinical studies in patients with atopic dermatitis

Amgen reports topline results from phase III study of adalimumab biosimilar in psoriasis

Teva Pharmaceutical begins rolling NDA for CEP-33237

Ruthigen begins phase I/II trial of RUT-5860

Patient enrollment under way in phase II trial of VPI-2690B in diabetic nephropathy

Nabriva Therapeutics granted FDA QIDP and fast track status for lefamulin

Bristol-Myers Squibb to begin a phase I/II study of BMS-986012 in small cell lung cancer

FDA grants priority review to Lucentis submission for diabetic retinopathy

RedoxTherapies licenses Vernalis' vipadenant for immuno-oncology applications

Regen BioPharma files IND application for autologous dendritic cell therapy for breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...